Keywords: world, immunology, rheumatology, markets, sandoz, sandimmun, ciclosporin
World Immunology, Rheumatology Markets
Article | 28 November 1994
Sandoz' Sandimmun (ciclosporin) accounted for 25.4% of the world market for immunologicals in 1993, with sales of $899 million. This puts it considerably ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
